1Armichael P,Popoola J,John I,et al.Assessment of quality of life in a single centre dialysis Population using the KDQOL-SF questionnaire[J].Qual Life Res,2000,9(2):195-205.
2Rao S,Carter WB,Mapes DL,et al.Development of subscales from the symptoms/problems and effects of kidney disease scales of the kidney disease quality of life instrument[J].Clin Ther,2000,22(9):1099-1111.
3Duarte PS,Miyazaki MC,Ciconelli RM,et al.Translation and cultural adaptation of the quality of life assessment instrument for chronic renal patients (KDQOL-SF)[J].Rev Assoc Med Bras,2003,49(4):375-381.
4Duarte PS,Ciconelli RM,Sesso R.Cultural adaptation and validation of the "Kidney Disease and Quality of Life-Short Form (KDQOL-SF? 1.3)"in Brazil[J].Braz J Med Biol Res,2005,38(2):261-270.
1Berthet P, Farine JC, Barras JP, et al. Calaium dobesilate: pharmacological profile related to its use in diabetic retinopathy [ J ]. Drug Focus, 1999, 53(8) : 631-636.
2Raij I, Azar S, Keane W. Mesangial immune injury, hypertension and progression glomerular damage in Dahl rats [ J ]. Kidney Int,1984, 26:137.
3Griffin KA, Picken MM, Churchill M, et al. Functional and structural correlates of glomerulosclerosis after renal mass reduction in the rat[J]. J Am Soc Nephrol, 2000. 11(3): 497-506.
4Kusano H, Muso E, Ono T, et al. Heminephrectomy causes the progression of glomerulosclerosis and apoptosis in high IgA strain ddY mice[J]. Nephron, 2002, 92(2):389-398.
5Gordge MP, Patel A, Faint RW, et al. Blood hyperviscosity and its relationship to progressive renal failure in patients with diabetic nephropathy[ J]. Diabet Med, 1990, 7:880-886.
6Kes P, Pecanic Z, Getaldie B, et al. Treatment of hyperviscosity syndrome in the patients with plasma cell dyscrasias [ J ]. Acta Med Croatica, 1996, 50(4-5) :173-177.
7McDonald KM. Influence of blood rheology on intrarenal blood flow distribution[ J]. Am J Physiol, 1976, 230(5 ) : 1448-1454.
8Anderson S, King A J, Brenner BM. Hyperlipidemia and glomerular sclerosis: an ahernative viewpoint[J]. Am J Med, 1989, 87(5N) :34N-38N.
9Tejerina T, Ruiz E. Calcium Dobesilate: Pharmacolopy and Future Approaches[ J ]. Gen Pharmac, 1998, 31 ( 3 ) : 357-360.
10Barras JP, Graf C. Hyperviscosity in diabetic retinopathy treated with Doxium( calcium dobesilate) [J]. Vasa, 1980,9(2): 161-164.
1Stenvinkel P, Heimbiirger O, Paultre F, et al. Strong association between malnutrition, inflammation and atherosclerosis in chronic renal failure[J]. Kidney Int, 1999,55 (5):1899-1911.
2Menon V, Wang X, Greene T, et al. Relationship between Creactive protein,albumin,and cardiovascular disease in patients with chronic kidney disease[J]. Am J Kidney Dis, 2003,42 (1) : 44-52.
3Kalantar-Zadeh K, Kleiner M, Dunne E, et al. A modified quantitative subjective global assessment of nutrition for dialysis patients [ J ]. Nephrol Dial Transplant, 1999, 14 ( 7 ) : 1732-1738.
4Tsirpanlis G, Bagos P, Ioannou D, et al. The variability and accurate assessment of microinflammation in hemodialysis patients[J]. Nephrol Dial Transplant,2004,19(1) .. 150-157.
5Hannaert P, Brunnet J, Farine JC, et al. Antioxidantangioprotective actions of calcium dobesilate in diabetic rats [J]. Int J Angiol,1999,8(1) :2-4.
6Descapmps Latscha B, Witko-Sarsat V. Importance of oxidatively modified proteins in chronic renal failure [J]. Kidney Int, 2001,78 (Suppl) : S108-113.
7Weiss MF, Erhard P, Kader Atria FA, et al. Mechanisms for the formation of glycoxidation products in end-stage renal disease[J]. Kidney Int,2000,57(6) :2571-2585.
8Tsirpanlis C,Bagos P,Ioannou D,et al.The variability andaccurate assessment of microinflammation in hemodialysis patients[J].Nephrol Dial Transplant,2004,19(1):150-157.
9Zafarullah M,Li WQ,Sylvester J,et al.Molecular mechanisms of N-acetylcysteine actions[J].Cell Mol life Sci,2003,60(1):6-20.
